Skip to content

Effects of consumption of the test food on the knee joint in healthy Japanese

Effects of consumption of the test food on the knee joint in healthy Japanese: a randomized, placebo-controlled, double-blind, parallel-group comparison study - Effects of consumption of the test food on the knee joint in healthy Japanese

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000059552
Enrollment
14
Registered
2025-10-27
Start date
2025-10-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese

Interventions

Duration: 12 weeks Test product: Supplement containing elastin peptides derived from horse Administration: Consume two capsules per day after lunch and before sleep Duration: 12 weeks Test product:

Sponsors

BIOCON (JAPAN) LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Japanese 2. Men or women 3. Adults (aged >= 40 and < 75 years) 4. Healthy individuals 5. Individuals who are judged in the Kellgren-Lawrence grade (KL grade) as 0 or 1 in X-ray at screening (Scr) 6. Individuals whose score of the JKOM measured by Visual Analogue Scale: (VAS) is high at Scr

Exclusion criteria

Exclusion criteria: 1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction 2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims" 5. Individuals who are taking or using medications (including herbal medicines) or supplements 6. Individuals who are allergic to medicines or foods related to the test product, particularly those who are allergic to horse-derived substances 7. Individuals who are pregnant, lactating, or planning to become pregnant during this study 8. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study 9. Individuals who usually use "Foods for Specified Health Uses," or "Foods with Functional Claims" {e.g. N-acetylglucosamine, proteoglycan from salmon nasal cartilage (SNC), undenatured type II collagen from SNC, glucosamine hydrochloride, curcumin, elastin peptide from skipjack, or collagen peptide} 10. Individuals who engage in intense, knee joint-loading exercise (e.g., ball sports such as soccer, baseball, basketball, or jogging, running, skiing, or snowboarding) 11. Individuals who use a cane or joint support, or may use them during this study 12. Individuals who are judged as ineligible to participate in this study by the physician

Design outcomes

Primary

MeasureTime frame
The measured values of the score of Japanese Knee Osteoarthritis Measure (JKOM) {visual analog scale (VAS)} at 12 weeks after consumption (12w)

Secondary

MeasureTime frame
1. The measured values of the score of JKOM (VAS) at 6 weeks after consumption (6w) 2. The measured values of total score, "Pain and stiffness in knees" score, "Conditions in daily life" score, "General activities" score, and "Health conditions" score of the JKOM at 6w and 12w 3. Individuals whose responses to each item in the JKOM improved by one or more scales at 6w and 12w 4. The measured values of the Japanese Orthopaedic Association (JOA) score (left/right averaged, left leg, and right leg), pain on walking (left/right averaged, left leg, and right leg), pain on ascending or descending stairs (left/right averaged, left leg, and right leg), range of motion (left/right averaged, left leg, and right leg), joint swelling (left/right averaged, left leg, and right leg), high-sensitivity C-reactive protein at 12w 5. Individuals whose JOA score improved by one or more scales at 12w

Countries

Japan

Contacts

Public ContactNaoko Suzuki

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026